It is the cache of ${baseHref}. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Validity of the recorded codes of gonadotropin-releasing hormone agoni
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14789

Validity of the recorded codes of gonadotropin-releasing hormone agonist treatment and orchiectomies in the Danish National Patient Registry



Original Research

(2463) Total Article Views


Authors: Jespersen CG, Borre M, Nørgaard M

Published Date June 2012 Volume 2012:4(1) Pages 145 - 149
DOI: http://dx.doi.org/10.2147/CLEP.S32313

Received: 27 March 2012
Accepted: 27 April 2012
Published: 18 June 2012
Christina Gade Jespersen,1,2 Michael Borre,1 Mette Nørgaard2

1Department of Urology, Aarhus University Hospital, Aarhus, Denmark; 2Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark

Purpose: Large-scale observational studies based on existing medical databases may have an important role in studies of long-term effects of different treatments in prostate cancer patients if the coding of the treatment is valid. We therefore estimated the positive predictive value (PPV) and negative predictive value (NPV) of hospital codes for gonadotropin-releasing hormone (GnRH) agonist treatment and orchiectomies in the Danish National Patient Registry (DNPR).
Patients and methods: From Danish prostate cancer patients we selected 100 patients who were registered as users of GnRH agonists, 100 patients who were registered as nonusers of GnRH agonists, 50 patients who were registered as bilateral orchidectomized, and 50 patients who were not registered as orchidectomized in the DNPR between January 1, 2002 and December 31, 2008. From the patients' medical files we recorded codes for GnRH agonist treatment and orchiectomies, including dates of treatment from date of first prostate cancer diagnosis and onward.
Results: The PPV of GnRH agonist treatment coding in the DNPR was 93% (95% confidence interval [CI]: 86.1–97.1), and the NPV was 94% (95% CI: 87.4–97.8). Both the PPV and NPV of orchiectomy coding in the DNPR were 100% (97.5% CI: 92.9–100).
Conclusion: We measured the validity of codes for GnRH agonist treatment and orchiectomies in the DNPR among prostate cancer patients and found high PPV and NPV. Thus, the DNPR remains a valuable tool for clinical epidemiological studies of GnRH agonist treatment and orchiectomies in the treatment of prostate cancer.

Keywords: prostate cancer, orchiectomy, positive predictive value, negative predictive value



Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: